How China's regulatory evolution is accelerating rare disease drug development

For many years, sponsors viewed China as a market that sat outside the main path of global drug development. Clinical programs were often designed around approvals in the United States and Europe, with China added later through standalone studies or bridging strategies.

However, over the past decade, China has implemented significant regulatory reforms designed to support innovation, accelerate the review of novel therapies and encourage participation in global clinical development. These changes are particularly important for rare disease sponsors, where speed, flexibility and early regulatory engagement can have a meaningful impact on development timelines.

How ICH regulatory alignment transformed rare disease drug development in China

One of the most important milestones in China's rare disease regulatory transformation was its decision to join the International Council for Harmonisation (ICH) in 2017. This move signalled a commitment to greater alignment with global regulatory standards and created new opportunities for multinational sponsors seeking more integrated development strategies.¹

Prior to these reforms, China was frequently incorporated into development plans after clinical programs were already well underway. This often resulted in additional studies, delayed submissions and extended timelines to reach patients.

Today, China actively encourages participation in multi-regional clinical trials (MRCTs), including studies that begin as early as Phase I development. By aligning with global development plans earlier, sponsors can create more efficient pathways to registration while generating data across broader patient populations.

Accelerated clinical trial approvals for rare disease studies

Speed is often a critical factor in rare disease drug development. Every month saved during development can represent earlier access to treatment for patients with limited therapeutic options.

China has introduced several reforms that have significantly accelerated clinical trial initiation. In 2018, the timeline for clinical trial application review was reduced to 60 working days. More recently, the National Medical Products Administration (NMPA) introduced measures intended to further optimize innovative drug development, including a 30-working-day review pathway for certain investigational new drug applications.² These changes have helped create a more predictable framework for sponsors evaluating China as part of a global development strategy.

Expedited regulatory pathways supporting innovation

Rare disease developers often face unique challenges because patient populations are small and unmet medical needs are high. To support innovation, China has established several expedited review mechanisms that may accelerate development and approval for qualifying products.

Key pathways include:

• Breakthrough Therapy Designation
• Priority Review and Approval
• Conditional Approval
• Special Approval pathways for clinically important therapies

These programs support regulatory flexibility when therapies demonstrate the potential to address serious conditions or significant unmet medical needs. Approval activity across these pathways has increased substantially in recent years, reflecting China's broader effort to encourage innovation.³

Increasing focus on rare diseases

Rare diseases have become a growing focus of regulatory policy in China. Recent guidance has encouraged the development of therapies for rare diseases while supporting more patient-centered approaches to research and development. In 2024, the NMPA launched the CARE (Patient-Centered Action for Rare Diseases Encouragement) Program, providing sponsors with opportunities for earlier and more frequent engagement with regulators throughout development.⁴ Building on this initiative, regulators have continued to strengthen support for innovative rare disease therapies, including the release of the 2026 CARE Program Extension guidance, which further reinforces the use of patient-centered development strategies and early regulatory dialogue for rare disease programs.⁵

The program promotes discussion around:

• Clinical development planning
• Study design
• Registration strategy
• Patient-focused development approaches
• Innovative evidence generation methods, including real-world evidence

China has also introduced additional incentives designed to support rare disease drug development. These include expedited review pathways, opportunities for conditional approval and regulatory protections intended to encourage innovation. For qualifying rare disease therapies, sponsors may be eligible for up to seven years of data protection and market exclusivity, creating an important incentive for investment in areas with significant unmet medical need. For sponsors navigating complex rare disease programs, these regulatory initiatives can provide greater clarity during development, support earlier alignment with regulators and create a more favorable environment for bringing innovative therapies to patients.

Greater flexibility in clinical development

Traditional randomized controlled trials are not always practical in rare diseases. Small patient populations, heterogeneous disease presentations and limited natural history data often require alternative approaches.

China's regulatory environment has increasingly recognized these realities. Regulators have expressed support for flexible trial designs, the use of real-world evidence and approaches that incorporate patient insights into development plans. In some circumstances, conditional approval may be supported through surrogate endpoints or single-arm clinical studies when clinically appropriate. These developments are particularly relevant for sponsors pursuing therapies in ultra-rare conditions where conventional development pathways may be difficult to execute.

A regulatory environment built for global development

China's regulatory reforms are not simply about accelerating domestic approvals. They are also intended to facilitate global drug development. The ability to include China earlier in development, leverage international clinical data and engage regulators throughout the process creates new opportunities for multinational organizations. Sponsors can increasingly view China as part of a synchronized development strategy rather than a separate regulatory destination.

China's evolving role in global rare disease drug development

The perception of China as a challenging regulatory environment is increasingly outdated. Through ICH alignment, accelerated review pathways, rare disease-focused initiatives and support for innovative trial designs, China has established a framework that is increasingly aligned with the needs of modern drug development.⁶

For rare disease sponsors, these reforms represent more than administrative improvements. They create opportunities to streamline development, engage patients earlier and bring innovative therapies to market more efficiently.

Learn more about how Fortrea can support your rare disease study. 

References

1. https://www.ich.org/pressrelease/ich-assembly-montreal-canada-mayjune-2017 
2. https://english.nmpa.gov.cn/2025-10/14/c_1138494.htm 
3. https://www.precisionformedicine.com/blog/chinas-new-drug-regulatory-framework-positions-the-country-as-a-global-hub-for-innovative-medicine-launches 
4. https://english.nmpa.gov.cn/2025-09/05/c_1138504.htm 
5. https://www.cde.org.cn/main/news/viewInfoCommon/3a028dc5479e8098013b33a83296ac3f 
6. https://ispe.org/pharmaceutical-engineering/march-april-2024/evolving-chinas-regulatory-system-alignment-ich